EUVIMEDEUVIMED entdecken
Crossref

circANKRD28 inhibits cisplatin resistance in non‐small‐cell lung cancer through the miR‐221‐3p/SOCS3 axis

Shu Song, Yuhan Shi, Dong Zeng, Jingjing Xu, Yuexiang Yang, Wenjuan Guo, Ye Zheng, Haicheng Tang iD

The Journal of Gene Medicine · 2023

DOI: 10.1002/jgm.3478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Gene Medicine, 2023. Verfasst von Shu Song und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, MicroRNAs, RNA, Circular. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non‐small‐cell lung cancer (NSCLC) is a common cancer. Chemotherapeutic drug resistance limits the therapeutic effect of NSCLC and leads to a poor prognosis. As a result, new specific targets may be better identified by studying the mechanism of drug resistance to cisplatin in NSCLC.

Methods

In the present study, we performed a quantitative real‐time polymerase chain reaction and western blotting to detect mRNA and protein levels. The proliferation of cells was analyzed by a Cell Counting Kit‐8 and colony formation assays. Cell invasion was measured via the Transwell assay. A scratch assay was performed to measure cell migration in cisplatin (DDP)‐resistant NSCLC cells. Apoptosis of cells was examined using flow cytometry.

Results

We found that circANKRD28 was notably decreased in NSCLC. The results showed that circANKRD28 expression was not affected, and its half‐life was more than 12 h. Functional experiments revealed that circANKRD28 overexpression inhibited DDP resistance in NSCLC cells in vitro. Mechanistic findings demonstrated that circANKRD28 regulated tumor cell progression and DDP sensitivity through the miR‐221‐3p/SOCS3 axis.

Conclusions

The present study revealed the regulatory effects and molecular mechanism of circANKRD28 on the development and cisplatin resistance in NSCLC, which may provide experimental basis and theoretical support to identify new targets for therapy of DDP resistance in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMicroRNAsRNA, CircularHumansCell Line, TumorCell ProliferationCisplatinDrug Resistance, NeoplasmSuppressor of Cytokine Signaling 3 ProteinIntracellular Signaling Peptides and Proteins

Stichwörter der Autor:innen

NSCLCchemotherapycircRNAmechanismmicroRNA

Substanzen

CisplatinMicroRNAsSuppressor of Cytokine Signaling 3 ProteinRNA, CircularMIR221, humanSOCS3 protein, humanANKRD28 protein, humanIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Department of Pathology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Department of Respiratory and Critical Care Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.

ORCID-Profile: Haicheng Tang

Zitieren

APA

Song, S., Shi, Y., Zeng, D., Xu, J., Yang, Y., Guo, W., Zheng, Y., & Tang, H. (2023). circANKRD28 inhibits cisplatin resistance in non‐small‐cell lung cancer through the miR‐221‐3p/SOCS3 axis. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.3478

Vancouver

Song S, Shi Y, Zeng D, Xu J, Yang Y, Guo W, et al. circANKRD28 inhibits cisplatin resistance in non‐small‐cell lung cancer through the miR‐221‐3p/SOCS3 axis. The Journal of Gene Medicine. 2023. doi:10.1002/jgm.3478

BibTeX
@article{Song2023,
  author = {Song, Shu and Shi, Yuhan and Zeng, Dong and Xu, Jingjing and Yang, Yuexiang and Guo, Wenjuan and Zheng, Ye and Tang, Haicheng},
  title = {circANKRD28 inhibits cisplatin resistance in non‐small‐cell lung cancer through the miR‐221‐3p/SOCS3 axis},
  journal = {The Journal of Gene Medicine},
  year = {2023},
  doi = {10.1002/jgm.3478}
}
Kostenlos starten →